Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model
Posttransplant cyclophosphamide (PTCy) is effective as prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) [1-5]. GVHD is still a major severe complication after HSCT; thus, the control of GVHD plays an essential role in improving survival after HSCT. Allogeneic HSCT is a curative treatment for patients with hematologic malignancy through the graft-versus-leukemia (GVL) effect, which is an anti-leukemia effect of donor-derived alloreactive T cells after HSCT [6]. (Source: Experimental Hematology)
Source: Experimental Hematology - April 23, 2023 Category: Hematology Authors: Yosuke Makuuchi, Yasuhiro Nakashima, Mitsutaka Nishimoto, Hideo Koh, Masayuki Hino, Hirohisa Nakamae Source Type: research
Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies
Patients with acute myeloid leukemia (AML) have a poor prognosis. The accumulation of genetic and nongenetic alterations in hematopoietic stem/progenitor cells (HSPCs) results in AML, and a growing body of evidence has provided ideas for leukemia prevention and interventions of preleukemic conditions [1 –4]. Approximately 10% of healthy adults aged over 65 years have leukemia-related mutations in hematopoietic cells, a condition called clonal hematopoiesis (CH) [5–7]. The leukemic transformation from this “preleukemic” status occurs in some high-risk patients who harbor multiple mutations i n specific genes (e.g., ...
Source: Experimental Hematology - April 20, 2023 Category: Hematology Authors: Koki Ueda Tags: Review Source Type: research
Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies
Patients with acute myeloid leukemia (AML) have a poor prognosis. The accumulation of genetic and nongenetic alterations in hematopoietic stem/progenitor cells (HSPCs) results in AML, and a growing body of evidence have provided ideas for leukemia prevention and interventions of preleukemic conditions [1 –4]. Approximately 10% of healthy adults aged over 65 have leukemia-related mutations in hematopoietic cells, a condition called clonal hematopoiesis (CH) [5–7]. Leukemic transformation from this “preleukemic” status occurs in some high-risk patients who harbor multiple mutations in specific genes (e.g., splicing f...
Source: Experimental Hematology - April 20, 2023 Category: Hematology Authors: Koki Ueda Tags: Review Source Type: research
Platycodin D induces proliferation inhibition and mitochondrial apoptosis in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease and represents the most common non-Hodgkin lymphoma (NHL) in adults, accounting for 30% - 40% of all newly diagnosed cases [1]. Two major molecular subtypes of DLBCL have been distinguished by gene expression profiling (GEP), the germinal center B-cell-like (GCB) DLBCL and the activated B-cell-like (ABC) DLBCL [2], while 10% - 15% of cases are identified as unclassified DLBCL [3]. It is noteworthy that the ABC subtype is associated with a worse prognosis than the GCB subtype [4,5]. (Source: Experimental Hematology)
Source: Experimental Hematology - April 19, 2023 Category: Hematology Authors: Pu Liu, Mengting Zhao, Ye Lin, Xia Jiang, Tianhao Xia, Youhong Li, Ying Lu, Lei Jiang Source Type: research
Ex vivo reprogramming of human hematopoietic stem cells is accompanied by increased transcripts of genes regulating metabolic integrity
The ability of the long-term (LT)- hematopoietic stem cells (HSCs) to balance self-renewal with commitment decisions is determined by a well-coordinated, unique transcriptomic and metabolic network [1 –12]. The transcriptome controls the functional fitness of the mitochondrial network required to meet the bioenergetic demands of HSCs during normal homeostasis, adaptation to stress, self-renewal, and differentiation [13–16]. On the other, apart from regulating oxidative stress and survival, mi tochondria can act as signaling hubs to dictate cell fate decisions by regulating the transcriptomic landscape [17–19]. (Sourc...
Source: Experimental Hematology - March 29, 2023 Category: Hematology Authors: Luena Papa, Tiphaine C. Martin, Mansour Djedaini, Mahtab Zangui, Umut Ozbek, Ramon Parsons, Ronald Hoffman, Christoph Schaniel Tags: Article Source Type: research
Reticulocyte mitochondrial retention increases reactive oxygen species and oxygen consumption in mouse models of sickle cell disease and phlebotomy-induced anemia
Sickle cell disease (SCD) is an inherited blood disorder that affects millions of people worldwide [1,2] and is caused by a point mutation within the β-globin gene, resulting in a substitution of valine for glutamic acid at position 6 in the β-globin chain. The abnormal β-globin chain combines with α-globin resulting in the production of hemoglobin S (HbS). HbS polymerizes on deoxygenation resulting in red cell fragility, hemolysis, and anemi a. In addition, those with SCD suffer from acute and chronic pain episodes, multisystem organ damage, and a shorter lifespan [3]. (Source: Experimental Hematology)
Source: Experimental Hematology - March 16, 2023 Category: Hematology Authors: Anne Gallivan, Mikail Alejandro, Amarachi Kanu, Nebeyat Zekaryas, Hart Horneman, Lenny K. Hong, Elliott Vinchinsky, Don Lavelle, Alan M. Diamond, Robert E. Molokie, Jagadeesh Ramasamy, Angela Rivers Tags: Article Source Type: research
Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era
Diffuse large B-cell Lymphoma (DLBCL) is a malignant lymphoma with a high incidence rate in adults. There are about 150,000 new DLBCL patients worldwide each year, accounting for 30-40% of the newly diagnosed non-Hodgkin's lymphoma (NHL) cases, while the incidence rate of the disease is 53.9% of NHL in China 1,2. DLBCL has not only a noticeable heterogeneity in clinicopathology, but also has diverse clinical characteristics. It is also complex and diverse in histomorphology, immunophenotype, biological behavior, and molecular genetics. (Source: Experimental Hematology)
Source: Experimental Hematology - March 16, 2023 Category: Hematology Authors: Xiping Liang, Renzhi Hu, Qiying Li, Chaoyu Wang, Yao Liu Tags: Review Source Type: research
Human umbilical cord mesenchymal stem cells ameliorate acute graft-versus-host disease by elevating phytosphingosine
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for malignant hematologic diseases. However, acute graft-versus-host disease (aGVHD) is currently the main complication limiting the wide application of transplantation [1,2]. Clinically, approximately 40% –60% of patients may develop aGVHD, resulting in transplant-related mortality of up to 5% and thus seriously affecting the long-term survival of patients [3]. With no consistently effective interventions for aGVHD and alternative approaches that are at best only modestly helpful, identification of more potent prophylactic and thera...
Source: Experimental Hematology - March 15, 2023 Category: Hematology Authors: Tao Hong, Rui Wang, Guancui Yang, Xiaoqi Wang, Lingyu Zeng, Shijie Yang, Jin Wei, Qiangguo Gao, Xi Zhang Tags: Article Source Type: research
Human umbilical cord mesenchymal stem cells ameliorate acute graft versus host disease by elevating phytosphingosine
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for malignant hematological diseases. However, acute graft-versus-host disease (aGVHD) is currently the main complication limiting the wide application of transplantation.1, 2 Clinically, approximately 40-60% of patients may develop aGVHD, resulting in transplant-related mortality of up to 5% and thus seriously affecting the long-term survival of patients.3 With no consistently effective interventions for aGVHD and alternative approaches that are at best only modestly helpful, identification of more potent prophylactic and therapeutic ...
Source: Experimental Hematology - March 15, 2023 Category: Hematology Authors: Tao Hong, Rui Wang, Guancui Yang, Xiaoqi Wang, Lingyu Zeng, Shijie Yang, Jin Wei, Qiangguo Gao, Xi Zhang Tags: Article Source Type: research
Inflammation-related mRNA expression in patients with multiple myeloma undergoing hematopoietic stem cell mobilization.
Multiple myeloma (MM) is a hematological disorder in which the clonal growth of neoplastic plasma cells in the bone marrow is observed [1]. According to the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO) recommendations, high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-SCT) is a standard therapy for newly diagnosed patients under 70 years of age [2]. For patients at high genetic risk or receiving bortezomib, cyclophosphamide, and dexamethasone (VCD) induction, tandem transplantation is recommended [2]. (Source: Experimental Hematology)
Source: Experimental Hematology - March 9, 2023 Category: Hematology Authors: Mateusz Nowicki, Agnieszka Wierzbowska, Bo żena Szymańska, Grzegorz Nowicki, Anna Szmigielska-Kapło Tags: Article Source Type: research
Cover 2: Editorial Board
(Source: Experimental Hematology)
Source: Experimental Hematology - March 1, 2023 Category: Hematology Source Type: research
Circulating cell-free mitochondrial DNA as a diagnostic and prognostic biomarker in chronic and late acute graft-versus-host disease in children
Chronic graft-versus-host disease (cGvHD) is a major long-term complication of hematopoietic stem cell transplantation (HSCT) resulting in high levels of morbidity and mortality post-HSCT [1]. Mitochondrial DNA (mtDNA) is a rich source of damage-associated molecular patterns (DAMPs), the only endogenous source of Toll‐like receptor 9 (TLR9) agonists resembling bacterial DNA [2], triggering pro‐inflammatory signaling pathways [3] on TLR9+ monocytes, macrophages, plasmacytoid dendritic cells, NK c ells, and B cells [4–6]. (Source: Experimental Hematology)
Source: Experimental Hematology - March 1, 2023 Category: Hematology Authors: Shima Azadpour, Sayeh Abdossamadi, Bernard Ng, Elena Ostroumov, Saeid Abroun, Geoffrey D.E. Cuvelier, Kirk R. Schultz Tags: Brief Communication Source Type: research
Circulating Cell Free Mitochondrial DNA As a Diagnostic and Prognostic Biomarker in Chronic and Late Acute Graft-versus-Host Disease in Children
Chronic graft-versus-host disease (cGvHD) is a major long-term complication of hematopoietic stem cell transplantation (HSCT) resulting in high levels of morbidity and mortality post-HSCT [1]. Mitochondrial DNA (mtDNA) represent a rich source of damage-associated molecular patterns (DAMPs), the only endogenous source of Toll‐like receptor 9 (TLR9) agonists resembling bacterial DNA [2], and triggering pro‐inflammatory signaling pathways [3] on TLR9+ monocytes, macrophages, plasmacytoid dendritic cells, NK cells, and B cells [4-6]. (Source: Experimental Hematology)
Source: Experimental Hematology - March 1, 2023 Category: Hematology Authors: Shima Azadpour, Sayeh Abdossamadi, Bernard Ng, Elena Ostroumov, Saeid Abroun, Geoffrey D.E. Cuvelier, Kirk R. Schultz Tags: Brief Communication Source Type: research
Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1low model of myelofibrosis
The word “emperipolesis” (from the Greek word meaning “inside wandering”) was first used by Humble et al in 1956 to describe the passage of cancer cells inside megakaryocytes (1). Later studies defined emperipolesis as the random passage of one cell through the cytoplasm of another with no pathologic al consequence for either one of them. It was then discovered that emperipolesis is particularly frequent in megakaryocytes since by transmission electron microscopy up to 5% of those present in a normal bone marrow section are engulfed with other cell types, including red blood cells and neutrophil s (2). (Source: Exp...
Source: Experimental Hematology - February 28, 2023 Category: Hematology Authors: Francesca Arciprete, Paola Verachi, Fabrizio Martelli, Mauro Valeri, Manjola Balliu, Paola Guglielmelli, Alessandro Maria Vannucchi, Anna Rita Migliaccio, Maria Zingariello Tags: Article Source Type: research
Glucose-6-phosphate dehydrogenase is dispensable for human erythroid cell differentiation in vitro
Hundreds of millions of people worldwide have a deficiency of glucose-6-phosphate dehydrogenase (G6PD), a predominant enzyme in the metabolism of erythrocytes [1]. G6PD is involved in the synthesis of reduced nicotinamide adenine dinucleotide phosphate (NADPH), an antagonist of oxidative stress. Consequently, G6PD-deficient erythrocytes are vulnerable to life-threatening hemolysis in peripheral blood when exposed to oxidation inducers [2]. In the absence of oxidative stress inducers, G6PD-deficient individuals are asymptomatic and live normally, implying normal erythrocyte production. (Source: Experimental Hematology)
Source: Experimental Hematology - February 17, 2023 Category: Hematology Authors: Kanyarat Boonpeng, Nutpakal Ketprasit, Attakorn Palasuwan, Kasem Kulkeaw, Duangdao Palasuwan Tags: Article Source Type: research
